{"id":185518,"date":"2026-06-25T07:56:22","date_gmt":"2026-06-25T13:26:22","guid":{"rendered":"https:\/\/newslink360.space\/?p=185518"},"modified":"2026-06-25T07:56:22","modified_gmt":"2026-06-25T13:26:22","slug":"hidradenitis-suppurativa-and-icis-amj","status":"publish","type":"post","link":"https:\/\/newslink360.space\/?p=185518","title":{"rendered":"Hidradenitis Suppurativa and ICIs &#8211; AMJ"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<p>    HIDRADENITIS suppurativa may newly develop or flare in some patients receiving immune checkpoint inhibitor therapy.<\/p>\n<h2>Hidradenitis Suppurativa During Cancer Immunotherapy<\/h2>\n<p>Immune checkpoint inhibitors have transformed cancer treatment, but their immune-mediated effects can extend beyond tumor control. A new scoping review suggests that <a href=\"https:\/\/www.emjreviews.com\/en-us\/amj\/dermatology\/news\/aad-2026-four-years-of-secukinumab-sustain-hs-control\/\" target=\"_blank\" rel=\"noopener\">hidradenitis suppurativa<\/a> may emerge after immune checkpoint inhibitor initiation or worsen in patients with pre-existing disease, highlighting a need for dermatologic awareness during oncologic care.<\/p>\n<p>Hidradenitis suppurativa is a chronic inflammatory skin disease characterized by recurrent abscesses, painful lesions, and long-term inflammatory burden. Although immune checkpoint inhibitors are widely used across oncology, their relationship with hidradenitis suppurativa onset, activity, and clinical course has remained poorly characterized.<\/p>\n<h2>Immune Checkpoint Inhibitors and HS Flares<\/h2>\n<p>The review identified five publications reporting 13 patients with hidradenitis suppurativa onset or worsening in the setting of immune checkpoint inhibitor therapy. Pembrolizumab was the most frequently reported agent, used in 46.2% of cases.<\/p>\n<p>Among the 13 patients, eight had pre-existing hidradenitis suppurativa. Of these, three experienced disease flares during immune checkpoint inhibitor therapy. Five patients developed new-onset hidradenitis suppurativa after treatment initiation, with onset reported within 2 to 4 months.<\/p>\n<p>These findings do not establish incidence or causality, but they suggest a clinically relevant pattern that may warrant attention, particularly in patients with a history of inflammatory skin disease.<\/p>\n<h2>Early Dermatology Input May Preserve Cancer Care<\/h2>\n<p>Management varied across the included cases and involved topical and systemic hidradenitis suppurativa therapies. Four patients experienced complete resolution of lesions after immune checkpoint inhibitor discontinuation.<\/p>\n<p>For clinicians, the key implication is not that immune checkpoint inhibitors should be avoided, but that new or worsening hidradenitis suppurativa symptoms should be recognized early. Timely dermatologic involvement may help confirm the diagnosis, guide therapy, reduce symptom burden, and support continuity of cancer treatment where appropriate.<\/p>\n<p>The small number of reported cases underscores the need for larger studies to clarify risk, disease course, and optimal management strategies. Until then, clinical vigilance is essential when patients receiving immune checkpoint inhibitors develop recurrent abscesses, inflammatory nodules, or hidradenitis suppurativa-like lesions.<\/p>\n<p><strong>Reference<\/strong><br \/>Marquez CR et al. The effects of immune checkpoint inhibitors on hidradenitis suppurativa: A scoping review. Skin Appendage Disord. 2026;doi:10.1159\/000551945.<\/p>\n<p>Featured Image: xxx on Adobe Stock.<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.emjreviews.com\/dermatology\/news\/hidradenitis-suppurativa-risk-emerges-with-immunotherapy\/\" target=\"_blank\" rel=\"noopener\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIDRADENITIS suppurativa may newly develop or flare in some patients receiving immune checkpoint inhibitor therapy. Hidradenitis Suppurativa During Cancer Immunotherapy Immune checkpoint inhibitors have transformed cancer treatment, but their immune-mediated&hellip;<\/p>\n","protected":false},"author":1,"featured_media":185519,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[],"class_list":["post-185518","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-national-news"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/newslink360.space\/wp-content\/uploads\/2026\/06\/AdobeStock_837966512.jpeg","jetpack_likes_enabled":true,"jetpack-related-posts":[{"id":181088,"url":"https:\/\/newslink360.space\/?p=181088","url_meta":{"origin":185518,"position":0},"title":"Shared T Cell Signatures Identified In IBD","author":"Ajay Kumar Verma","date":"June 16, 2026","format":false,"excerpt":"IBD\u00a0linked\u00a0T cell receptor\u00a0(TCR)\u00a0specificity driven by HLA-DRB1 is associated with shared antigen targets and distinct CD4+\u00a0memory T cell signatures across ulcerative colitis and Crohn\u2019s disease. The findings highlight how genetic risk contributes to shaping immune recognition patterns in IBD and may underpin shared inflammatory pathways across disease phenotypes.\u00a0 HLA-DRB1 Driven T\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/Gastro-12pm-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/Gastro-12pm-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/Gastro-12pm-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/Gastro-12pm-1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":175949,"url":"https:\/\/newslink360.space\/?p=175949","url_meta":{"origin":185518,"position":1},"title":"Breakthrough drug nearly doubles survival with advanced pancreatic cancer \u2013 an oncologist explains how daraxonrasib overcame an \u2018undruggable\u2019 disease &#8211; The Conversation","author":"Ajay Kumar Verma","date":"June 2, 2026","format":false,"excerpt":"Breakthrough drug nearly doubles survival with advanced pancreatic cancer \u2013 an oncologist explains how daraxonrasib overcame an \u2018undruggable\u2019 disease\u00a0\u00a0The ConversationDaily pill doubles survival time for pancreatic cancer patients\u00a0\u00a0BBC\u2018Landmark\u2019 pancreatic cancer drug keeps patients alive for twice as long\u00a0\u00a0The Washington PostDaily pill can double survival time for world\u2019s deadliest cancer, trial\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/05\/J6_coFbogxhRI9iM864NL_liGXvsQp2AupsKei7z0cNNfDvGUmWUy20nuUhkREQyrpY4bEeIBucs0-w300-rw.webp?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":183478,"url":"https:\/\/newslink360.space\/?p=183478","url_meta":{"origin":185518,"position":2},"title":"AKAP1 Metabolic Pathway Drives Liver Cancer Growth","author":"Ajay Kumar Verma","date":"June 21, 2026","format":false,"excerpt":"KEY driver of liver cancer growth identified in a new study suggests that a mitochondrial protein may play a central role in reprogramming how cells store and utilise glycogen, highlighting a previously underappreciated metabolic pathway in cancer development and offering a potential new therapeutic target for hepatocellular carcinoma (HCC). The\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":185452,"url":"https:\/\/newslink360.space\/?p=185452","url_meta":{"origin":185518,"position":3},"title":"GI Severity and Renal Involvement in IgA Vasculitis","author":"Ajay Kumar Verma","date":"June 25, 2026","format":false,"excerpt":"SEVERE gastrointestinal involvement in paediatric IgA vasculitis is associated with renal involvement in children, according to a retrospective single centre cohort study examining clinical characteristics, gastrointestinal manifestations and renal outcomes between August 2023 and June 2024. Paediatric IgA Vasculitis and Renal Involvement IgA vasculitis is characterised by IgA dominant immune\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/11am-Neph.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/11am-Neph.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/11am-Neph.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/11am-Neph.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":174807,"url":"https:\/\/newslink360.space\/?p=174807","url_meta":{"origin":185518,"position":4},"title":"New genomic test may help millions of breast cancer patients avoid chemotherapy &#8211; CNBC TV18","author":"Ajay Kumar Verma","date":"May 30, 2026","format":false,"excerpt":"New genomic test may help millions of breast cancer patients avoid chemotherapy\u00a0\u00a0CNBC TV18Millions of breast cancer patients could safely avoid chemotherapy, study suggests\u00a0\u00a0BBCGroundbreaking genomic test could spare millions of breast cancer patients chemotherapy\u00a0\u00a0The GuardianSkip the chemo: Millions of breast cancer patients could be spared chemotherapy with groundbreaking genomic test\u00a0\u00a0The Times\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/05\/J6_coFbogxhRI9iM864NL_liGXvsQp2AupsKei7z0cNNfDvGUmWUy20nuUhkREQyrpY4bEeIBucs0-w300-rw.webp?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]},{"id":182594,"url":"https:\/\/newslink360.space\/?p=182594","url_meta":{"origin":185518,"position":5},"title":"Hypopigmented Mycosis Fungoides Shows Low Risk","author":"Ajay Kumar Verma","date":"June 19, 2026","format":false,"excerpt":"A LARGE multicentre cohort study has found that hypopigmented mycosis fungoides (HMF) in adults generally follows an indolent clinical course, with most patients presenting with early-stage disease and responding well to skin-directed therapies. Insights from a Multicentre Hypopigmented Mycosis Fungoides Study The retrospective study analysed 224 adults with biopsy-confirmed HMF\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/2pm-derm-5.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/2pm-derm-5.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/2pm-derm-5.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/2pm-derm-5.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pgnRh4-Mge","_links":{"self":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/185518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=185518"}],"version-history":[{"count":0,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/185518\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/media\/185519"}],"wp:attachment":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=185518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=185518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=185518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}